康希诺生物股份公司 Consino Biological Inc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing 2022-05-19 23:28
CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research 2022-04-25 08:00
CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China 2022-04-04 08:30
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia 2022-03-22 21:32
Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant 2022-03-14 08:00
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China 2022-02-21 08:05
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster 2022-01-11 15:15
CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China 2022-01-09 10:09
Convidecia™ Phase III Results Published in The Lancet 2021-12-24 15:28
CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™ 2021-05-24 17:00
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile 2021-04-08 21:17
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary 2021-03-23 00:43
CanSinoBIO's Successful Listing on STAR Market Makes it the Initial Dual Listing Vaccine Company 2020-08-13 10:00
1